Shenzhen Hongxin Biotechnology

About Shenzhen Hongxin Biotechnology

Shenzhen Hongxin Biotechnology Co., Ltd., also known as MagicRNA, is a clinical-stage biotechnology company founded in 2021 and headquartered in Shenzhen, China. The company focuses on developing RNA drugs and advancing nucleic acid delivery technologies to treat a range of diseases, including cancer, infectious diseases, and autoimmune disorders like Systemic Lupus Erythematosus (SLE).

MagicRNA has developed three core technology platforms: an mRNA sequence design platform, an mRNA synthesis platform, and a lipid nanoparticle (LNP) delivery platform. A key component of their technology is the proprietary Engineered Cell-targeted LNP (EnC-LNP) platform, which enables the precise delivery of mRNA to specific cells beyond the liver, overcoming a significant limitation of conventional LNP systems. The company has created an extensive ionizable amino lipid library to support this platform.

The firm's business model includes providing custom mRNA synthesis and LNP encapsulation services to other biotech and pharmaceutical clients. MagicRNA's pipeline features infectious disease mRNA vaccines, mRNA tumor vaccines, and protein replacement therapies. Their lead candidate, HN2301, is an in vivo CAR T-cell therapy for treating refractory SLE. In September 2025, the company published first-in-human clinical data for HN2301 in The New England Journal of Medicine, demonstrating its ability to generate functional CAR T-cells directly within a patient's body.

Since its inception, MagicRNA has secured significant funding, including a Series A round in December 2025 with investors such as MPC, Tencent Investment, and IDG Capital. The company has established research and development labs in Shenzhen, with a team where over 80% hold a master's degree or higher, and collaborates with institutions like Sun Yat-sen University Affiliated Hospital.